Article thumbnail

Engineering of Therapeutic Proteins Production in Escherichia coli

By Mariusz Kamionka


Low cost and simplicity of cultivating bacteria make the E. coli expression system a preferable choice for production of therapeutic proteins both on a lab scale and in industry. In addition straightforward recombinant DNA technology offers engineering tools to produce protein molecules with modified features. The lack of posttranslational modification mechanisms in bacterial cells such as glycosylation, proteolytic protein maturation or limited capacity for formation of disulfide bridges may, to a certain extent, be overcome with protein engineering. Protein engineering is also often employed to improve protein stability or to modulate its biological action. More sophisticated modifications may be achieved by genetic fusions of two proteins. This article presents a variety of examples of genetic engineering of therapeutic proteins. It emphasizes the importance of designing a construct without any unnecessary amino acid residues

Topics: Article
Publisher: Bentham Science Publishers
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1994). A rapidly absorbed analogue of human insulin. Diabetes,
  2. (2007). Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis
  3. (2004). AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure.
  4. (2006). Albumin-interferon- in the treatment of chronic hepatitis C. Future Virol.,
  5. (2002). Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys.
  6. (2001). Asn to Lys mutations at three sites which are Nglycosylated in the mammalian protein decrease the aggregation of Escherichia coli-derived erythropoietin. Protein Eng.,
  7. (1984). Binding of 125I-labeled recombinant beta interferon (IFN-beta Ser17) to human cells.
  8. (2008). Biotechnology; 3 rd ed.; Informa Healthcare:
  9. (1987). Comparison of human and porcine insulin therapies in children with newly diagnosed diabetes mellitus. Diabetologia,
  10. (1985). Comparison of the biological activities of human recombinant interleukin-2(125) and native interleukin-2.
  11. (2003). Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin.
  12. (2005). Development of a long-acting insulin analog using albumin fusion technology. Diabetes,
  13. (2006). Effects of protein aggregates: an immunologic perspective.
  14. (1997). Engineering hyperactive variants of human deoxyribonuclease I by altering its functional mechanism. Biochemistry,
  15. (2006). Enhanced stability of recombinant keratinocyte growth factor by mutagenesis. Protein Eng. Des. Sel.,
  16. (2003). Enhancement of therapeutic protein in vivo activities through glycoengineering.
  17. (1979). Expression in Escherichia coli of chemically synthesized genes for human insulin.
  18. (2001). From cattle, swine, and horse insulin to human insulin: the biotechnology and genetic technology of insulin production. Pharm. Unserer Zeit.,
  19. (1985). Functional comparison of recombinant interleukin 2 (IL-2) with IL-2-containing preparations derived from cultured cells. Cell Immunol.,
  20. (1999). High-yield purification of biosynthetic human growth hormone secreted in Escherichia coli periplasmic space.
  21. Human growth hormonetransferrin fusion protein for oral delivery in hypophysectomized rats.
  22. (1983). Human insulin from recombinant DNA technology. Science,
  23. (2001). Increased production of human proinsulin in the periplasmic space of Escherichia coli by fusion to
  24. (1988). Monomeric insulins obtained by protein engineering and their medical implications. Nature,
  25. (2007). Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapyinduced mucositis.
  26. (2005). Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice. Cancer Immunol. Immunother.,
  27. (1983). Production, Characterization and Biological Effects of Recombinant
  28. (2005). Recombinant granulocyte colonystimulating factor-transferrin fusion protein as an oral myelopoietic agent.
  29. (2011). Recombinant human granulocyte colony-stimulating factor: effects 274 Current Pharmaceutical Biotechnology,
  30. (2001). Selective in vitro glycosylation of recombinant proteins: semisynthesis of novel homogeneous glycoforms of human erythropoietin.
  31. (1979). Semi-synthesis of human insulin by trypsin-catalysed replacement of Ala-B30 by Thr in porcine insulin. Nature,
  32. (1996). The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon.
  33. (2008). The function of the human interferon-beta 1a glycan determined in vivo.
  34. (2008). The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
  35. (2004). The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.
  36. (1997). The new era of biotech insulin analogues.
  37. (2010). The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution.
  38. (2009). The role of thiols and disulfides on protein stability.
  39. (2005). Transferrin: structure, function and potential therapeutic actions. Drug Discov. Today,